Diving Deep into Immune Checkpoint Inhibitors

This deep dive focuses on the value of ePROs in managing immune-related adverse effects and the impact this has on patient wellbeing and outcomes. It also considers the value and potential of the real-world data collected within the context of patients’ environments, and how this longitudinal view of patient wellbeing and treatment progression gives pharma companies a competitive advantage within the market.